Ibex Investors’s Rigel Pharmaceuticals RIGL Stock Holding History

Ibex Investors’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-7,932	Closed	-$281K	–	225
2018 Q1	$281K	Buy	+7,932	New	+$317K	0.23%	171

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

MWNA

Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Ibex Investors's RIGL Position: Q2 2018 in Review

Ibex Investors sold out of Rigel Pharmaceuticals (RIGL) in Q2 2018, closing a stake of 7,932 shares — an estimated $281K sold.

Ibex Investors first reported a position in RIGL in Q1 2018 and held it in 1 quarter. The position peaked at $281K in Q1 2018. 131 funds tracked by Wall St. Rank hold RIGL as of Q2 2018.

Ibex Investors reported no remaining Rigel Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Ibex Investors sold 7,932 Rigel Pharmaceuticals shares in Q2 2018, an estimated $281K.
Ibex Investors first reported a position in Rigel Pharmaceuticals in Q1 2018 and held it in 1 quarter.
Ibex Investors's Rigel Pharmaceuticals position peaked at $281K in Q1 2018.
131 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2018.

Based on Ibex Investors's 13F filing for Q2 2018, filed 14 Aug 2018.